Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-Drug Desensitization for Heart Transplant Candidates
NCT01556347Phase 2Terminated
- Start
- Jul 2012
- Primary completion
- May 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in Human Leukocyte Antigen Sensitization, heart transplant rejection. Started Jul 2012; status: terminated.
02
Drugs
bortezomib
03
Conditions
Human Leukocyte Antigen Sensitizationheart transplant rejection
Beyond the preview
Go deeper on NCT01556347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01556347.